GLP-1 and SGLT-2 drugs may be the best treatments for people with type 2 diabetes and COPD. Image credit: Visual Vic/Getty Images. Researchers estimate that as of 2019, about 400 million people around ...
Add Yahoo as a preferred source to see more of our stories on Google. AstraZeneca's IL-33 blocker AstraZeneca’s first-in-class biologic, tozorakimab, has posted a double Phase III win in chronic ...
For patients with chronic obstructive pulmonary disease (COPD), the Global Initiative on Obstructive Lung Disease recommends long-term term pharmacologic and nonpharmacologic therapies based on each ...
The first one was that several participants did not know the correct inhaler regimen that they were actively prescribed at ...
A new study published in the Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation shows how an innovative phone-based inhaler education program helped Medicare Advantage ...
Recent medical research reveals promising developments in the treatment of patients suffering from both diabetes and chronic obstructive pulmonary disease. The study, involving nearly 394,000 adults, ...
The U.S. Food and Drug Administration on Tuesday approved the first generic Symbicort drug used to treat asthma and chronic obstructive pulmonary disease (COPD), which are two common pulmonary health ...
Among adults with COPD, those with vs. without cost-related nonadherence had worse symptom burden, health status and lung ...
(Yicai) April 13 -- Shares of Haisco Pharmaceutical Group rose after the Chinese drugmaker granted US peer AbbVie the global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results